We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVIV
101
CALL
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
0
– –
VRTX icon
102
Vertex Pharmaceuticals
VRTX
$121B
$1.85M 0.09%
23,320
+13,320
+133% +$1.2M
MCRB icon
103
Seres Therapeutics
MCRB
$48M
$1.84M 0.09%
3,464
+2,939
+560% +$1.53M
ACUR
104
DELISTED
Acura Pharmaceuticals
ACUR
$1.84M 0.09%
648,884
-78,981
-11% -$168K
CEMP
105
CALL
DELISTED
Cempra, Inc.
CEMP
$1.83M 0.09%
1,044
+668
+178% +$12.1K
SGMO
106
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.82M 0.09%
3,005
+1,780
+145% +$10.7K
BDSI
107
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.8M 0.09%
555,969
-61,527
-10% -$227K
KDNY
108
CALL
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.79M 0.09%
+280
New +$22.6K
GWPH
109
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.77M 0.09%
24,603
-135,803
-85% -$7.45M
CRDC
110
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.77M 0.09%
498,600
-358,318
-42% -$1.04M
ACHN
111
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$1.77M 0.09%
2,298
-3,580
-61% -$26.2K
CEMP
112
DELISTED
Cempra, Inc.
CEMP
$1.75M 0.09%
100,000
+5,237
+6% +$95K
FOMX
113
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.7M 0.08%
260,400
+22,000
+9% +$142K
BMY icon
114
CALL
Bristol-Myers Squibb
BMY
$127B
$1.69M 0.08%
264
-1,385
-84% -$87.3K
RLYP
115
DELISTED
RELYPSA INC COM
RLYP
$1.67M 0.08%
+122,905
New +$2.09M
PRTA icon
116
Prothena Corp
PRTA
$458M
$1.65M 0.08%
+40,000
New +$1.57M
CSCI
117
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$1.64M 0.08%
4,925
-416
-8% -$137K
KITE
118
CALL
DELISTED
Kite Pharma, Inc.
KITE
$1.63M 0.08%
+605
New +$29.3K
ADYX
119
DELISTED
Adynxx Inc
ADYX
$1.61M 0.08%
32,787
+21,707
+196% +$1.74M
GALT icon
120
Galectin Therapeutics
GALT
$229M
$1.53M 0.08%
1,072,765
-13,850
-1% -$18.6K
LPCN icon
121
Lipocine
LPCN
$17.1M
$1.53M 0.08%
8,887
-67
-0.7% -$11.4K
PGNX
122
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.5M 0.08%
+345,197
New +$1.54M
HZNP
123
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.5M 0.08%
+908
New +$15.9K
COLL icon
124
Collegium Pharmaceutical
COLL
$1.14B
$1.49M 0.07%
+82,100
New +$1.49M
ASRT
125
DELISTED
Assertio
ASRT
$1.48M 0.07%
+1,768
New +$1.64M
3 4
5
6 7

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.